1Rossi E. Cardiovascular disease in diabetes and operative risk. Rays,1997,22(4) : 595-602
2Pas AK. Specific heart muscle disease in diabetes mellitus a functional structural conelation. Int J Cardiol, 1987, 17:299-302
3David SH. Diabetic cardiomyopathy a unique entity or a complication of coronary artery disease. Diabetes Care, 1995,18 : 708
4Schannwell CM, Schoebel FC, Heggen S, et al. Early decrease in diastolic function in young type Ⅰ diabetic patients as an initial manifestation of diabetic cardiomyopathy. Z Kardiol, 1999,88(5):338
5Di Bello V, Glampietro O, Matteucci E, et al. Ultrasonic tissue characterization analysis in type 1 diabetes: a very early index of diabetic cardiomyopathy? G Ital Cardiol, 1998,28(10) : 1128-1137
6Pandit SV, Giles WR, Demir SS. A mathematical model of the electrophysiological alterations in rat ventricular myocytes in type-Ⅰ diabetes. Biophy J,2003,84:832-841
8Kroncke KD, Seyler H. Nitric oxide generation during cellular metabolization of the diabetogenic N-methyl-N-nitroso-urea streptozotozin contributes to islet cell DNA damage. Biol Chem, 1995,376:379
9Thomas G, Ramwell P. Streptozotocin: a nitric oxide carrying molecule and its effect on vasodilation. Eur J Pharmacol, 1989, 61:79
10Szkudelski T. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res, 2001,50:537
